Midven backs Alzheimer’s research

Cytox, a university spin-out that creates diagnostics tests and therapeutic cures for Alzheimer’s disease, has raised £1.25 million from Midven, NESTA and angel investors including members of Cambridge Angels and Cogent Lifesciences.


Cytox, a university spin-out that creates diagnostics tests and therapeutic cures for Alzheimer’s disease, has raised £1.25 million from Midven, NESTA and angel investors including members of Cambridge Angels and Cogent Lifesciences.

Cytox, a university spin-out that creates diagnostics tests and therapeutic cures for Alzheimer’s disease, has raised £1.25 million from Midven, NESTA and angel investors including members of Cambridge Angels and Cogent Lifesciences.

Birmingham-based Cytox was spun out from Oxford University and is the 63rd company to be created with the University’s IP. It is developing a blood test that checks for cell abnormalities and can identify the disease before a patient develops dementia.

Cytox has already secured £650,000 in a funding round led by Midven in December 2006. The company aims to start major clinical trials within two years.

Cytox’s chief executive Richard Hadden, who formerly worked at NESTA, says: ‘The effect of our work should very quickly have a dramatic effect on research into Alzheimer’s disease. We have already established a dialogue with a number of pharmaceutical companies who recognise the value of our new approach.’

Marc Barber

Marc Barber

Marc was editor of GrowthBusiness from 2006 to 2010. He specialised in writing about entrepreneurs, private equity and venture capital, mid-market M&A, small caps and high-growth businesses.

Related Topics